When acne treatment irritates: the questions to ask before a patient gives up

When acne treatment irritates, a useful review starts with the patient’s symptoms, the routine they actually use and what is getting in the way. Clinical evidence supports selected measures to improve comfort, including suitable moisturising and medicine-specific application adjustments. The aim is an effective, manageable treatment plan that the patient understands and can follow.^{1, 6, 7, 8}

Key messages

• Ask about discomfort and actual treatment use even when acne lesions are improving.^{2, 3}

• Check practical barriers such as cost, confusion and routine complexity alongside side effects.^{2, 11}

• Gentle cleansing and suitable moisturising can support tolerability; assess comfort, adherence and acne response as separate outcomes.^{1, 6, 7, 9}

• Agree a medicine-specific plan, clear follow-up and access to earlier help for substantial or concerning reactions.^{8, 10}

What is bothering the patient, and what would a worthwhile result look like?

Start with: “What is bothering you most about your skin or treatment now?” The answer may be painful application, continuing breakouts, residual dark or red marks, scars or a routine that is difficult to manage. Let that concern emerge before explaining the lesion count.

These are conversation prompts rather than a validated score. They apply the principle of discussing concerns, perceived response and satisfaction throughout care, described in the Personalised Acne Care Pathway expert recommendations.³

Clarify whether the desired improvement concerns acne activity, colour changes, texture or comfort. These can need different assessments. Ask how the skin affects confidence, mood and daily activities, and discuss significant distress sensitively. Acne can affect mental health, while dissatisfaction alone does not establish a psychiatric diagnosis.^{3, 4}

Invite questions about previous experiences or online advice: “Is there anything you have seen or heard that you would like us to talk through?” Summarise the main concern and invite correction. A visible clinical improvement should not prevent a discussion of what remains difficult.

What is being applied, and when do symptoms occur?

Ask the patient to describe everything they use, or bring products or photographs of their labels. Establish the medicine, strength and formulation, the amount applied, frequency and areas treated. Review cleansers, moisturisers, exfoliants and additional non-prescription acne products.

Connect symptoms to that history. When did they start? Did they follow a new medicine, more frequent use or an added product? Do they persist between applications? Have they led to missed doses or reduced use?

Topical retinoids such as adapalene and tretinoin, benzoyl peroxide and salicylic acid can all be relevant to dry or irritated skin. Oral isotretinoin needs a separate medicine-specific discussion rather than advice copied from topical treatment.^{1, 8, 9, 10}

Ask about sensations as well as appearance. Redness may be harder to recognise on black or brown skin, so heat, itching, pain and peeling can help describe the experience. Retinoid irritation does not usually mean allergy, but an uncertain or substantial reaction still needs assessment. Pronounced pain or extensive peeling is not evidence that a treatment is working better.^{8, 10}

Has treatment started, and what makes regular use difficult?

First establish whether the patient obtained and started the treatment. Barriers before starting, such as cost, confusion or fear of reactions, may differ from difficulties that arise later.¹¹

After treatment begins, perceived lack of results, side effects, complexity, forgetting, inconvenience and a busy routine can interfere with use. Neutral wording is helpful: “In a typical week, how often are you able to apply it?” Then ask what makes the other applications difficult.¹¹

Check repeat-supply costs and the cost of supporting products. A short routine can still be unaffordable. Match support to the problem: explanation may address uncertainty, a clinically appropriate simpler plan may reduce complexity, and reminders may help forgetting. A reminder will not solve painful application or an unaffordable prescription. Evidence for individual adherence interventions remains limited, so review whether the chosen support actually helps.¹¹

How can supportive skincare improve comfort?

Gentle cleansing and suitable moisturising can support a regimen that causes dryness or irritation. The National Institute for Health and Care Excellence (NICE) acne guideline recommends twice-daily non-alkaline synthetic detergent, or syndet, cleansing. Expert recommendations also support suitable moisturisers alongside retinoids and benzoyl peroxide.^{1, 12, 16}

Moisturising helps retain water in the outer skin. The American Academy of Dermatology (AAD) advises selecting an acne-friendly formula, for example one labelled non-comedogenic, meaning intended not to clog pores. Applying moisturiser after washing helps trap water; its timing relative to medication should follow the actual medicine’s instructions.⁹

Review scrubs, toners and overlapping exfoliating products before adding more steps. Ask about comfort, texture preferences and affordability. Ceramides and niacinamide appear in studied formulations, but the complete product and the patient’s response matter more than the ingredient name alone.^{12, 13}

For patients receiving oral isotretinoin, L’Oréal Dermatological Beauty Pro provides further professional learning on supportive ceramide skincare during isotretinoin treatment. The resource introduces formulation-specific research; its title should not be treated as proof that every ceramide regimen improves treatment continuation.

What does research tell us about tolerability and adherence?

Dryness and irritation can be an obstacle to treatment use, alongside cost and perceived response. A 2026 systematic review of observational studies found these among the reasons for non-adherence, with estimates varying substantially according to population and measurement. Ask the individual patient what actually happens rather than predict use from a symptom alone.^{1, 2}

Scroll horizontally to view the full table.

Improving comfort is worthwhile in its own right. Some studies also report better adherence, but that outcome must be measured separately. A survey of 3,139 acne patients cited by the adult-acne consensus associated cleanser and moisturiser use with better adherence; the association does not establish that skincare caused it.⁶

Study discontinuation is also different from missed applications. A review of topical-antimicrobial trials found generally good tolerability and low discontinuation with little relationship between the two, while excluding retinoid combinations. Trial use may differ from everyday practice. Someone can continue a prescription while using it much less often than agreed.⁵

Use each finding for the question it addresses: symptoms for comfort, actual use for adherence, and lesion assessment for acne control. Similar lesion reductions in a trial do not by themselves establish treatment equivalence.^{2, 7}

When should the prescribed regimen change?

If discomfort interferes with use, review the prescribed regimen as well as supporting products. AAD guidance describes clinician-led options for retinoids, including a smaller amount, less frequent use or moisturiser first. Patients should make these changes with the treating clinician’s help.⁸

The vehicle, meaning the formulation carrying the medicine, also deserves consideration. The EuroGuiDerm European acne-treatment guideline identifies vehicle choice as relevant to topical efficacy and tolerability. It does not imply that changing every gel to a lotion will solve irritation.¹⁷

Nurses and pharmacists can check understanding, identify discrepancies and involve the prescriber when needed. The alternate-night or short-contact schedules studied with one adapalene/benzoyl peroxide formulation are not automatic instructions for other medicines. The trial also does not establish a standard treatment break or restart schedule.⁷

Simplify where complexity is the barrier, while retaining the clinical purpose of each prescribed step. Agree what continues, what changes and when it will be reviewed rather than leave the patient to make repeated, unplanned adjustments.¹¹

Which symptoms need earlier advice or urgent help?

Troublesome or persistent symptoms deserve advice. Pronounced pain, marked swelling, blistering or a worsening reaction should prompt assessment rather than reassurance that the skin is simply adjusting. Check the safety information for the actual medicine.

National Health Service (NHS) benzoyl peroxide guidance lists hot, itchy or painful skin, redness, dryness and peeling among common effects. It advises speaking to a pharmacist or doctor if effects bother the patient or do not go away.¹⁰

Rarely, benzoyl peroxide can cause anaphylaxis, a serious allergic reaction. Difficulty breathing or swelling of the throat or tongue requires immediate emergency help through the local emergency service. This medicine-specific warning is not a complete triage protocol for every acne treatment.¹⁰

Expected treatment timelines should never become a reason to wait through a potentially serious reaction.

Where can dependable information support the conversation?

Match the source to the question. AAD patient pages explain retinoid irritation, clinician-guided adjustments and acne-friendly moisturising. NHS medicine guidance covers common benzoyl peroxide effects and serious-reaction warnings.^{8, 9, 10}

Use the leaflet supplied with the actual medicine for application and safety details, alongside local professional advice. Adapt emergency contact directions to the patient’s location rather than copying a UK number into international counselling.¹⁰

For clinical recommendations, the AAD acne guideline and NICE acne guidance are useful starting points. Check the relevant recommendation before attributing an initiation or adjustment schedule to an organisation; a guideline overview is not a substitute for the detail.^{14, 15, 16}

When reading research, distinguish self-reported use, prescription records, treatment discontinuation, satisfaction and lesion response. They describe different aspects of care. Population, medication, comparator, duration and the stated outcome determine how the finding can inform the patient’s plan.^{2, 5, 7}

What should the agreed follow-up plan contain?

End with a plan that responds to the identified concern. Painful application may need a tolerability review, continuing acne needs assessment of response and use, and cost or confusion needs a feasible solution. Marks, scars and psychosocial concerns may need separate attention.³

Explain initial improvement and the fuller treatment response separately. AAD advice notes that fewer breakouts may take at least six to eight weeks to appear, while the Personalised Acne Care Pathway recommendations explain that optimal results generally take several months. Neither is a clearance guarantee or an instruction to endure a serious reaction.^{3, 8}

• Record the patient’s main concern and agreed priority.

• Specify what continues or changes and how each treatment should be used.

• Agree which signs of progress and symptoms will be reviewed.

• Set the review arrangements and explain how to obtain earlier advice.

Demonstrate application where useful and ask the patient to describe the plan in their own words. At follow-up, review acne activity, comfort, actual use and satisfaction together. The aim is appropriate treatment that works in the patient’s life, rather than continued use at any cost.^{3, 8}

References

1. Lynde CW, Andriessen A, Barankin B, et al. Moisturizers and ceramide-containing moisturizers may offer concomitant therapy with benefits. J Clin Aesthet Dermatol. 2014;7(3):18–26. View source ↗
2. pubmed.ncbi.nlm.nih.gov. Treatment adherence in acne vulgaris: systematic review and narrative synthesis [Internet]. Accessed 3 November 2026. View source ↗
3. pmc.ncbi.nlm.nih.gov. The Personalised Acne Care Pathway—Recommendations to guide longitudinal management from the Personalising Acne: Consensus of Experts [Internet]. Accessed 3 November 2026. View source ↗
4. NHS. Acne - NHS [Internet]. Accessed 3 November 2026. View source ↗
5. pubmed.ncbi.nlm.nih.gov. Tolerability of topical antimicrobials in treatment of acne vulgaris [Internet]. Accessed 3 November 2026. View source ↗
6. Baldwin HE, Ablon G, Callender V, et al. Challenges in Adult Acne and the Role of Skin Care in Managing the Condition. J Drugs Dermatol. 2024;23(8):674–679. doi:10.36849/JDD.8471. View source ↗
7. pubmed.ncbi.nlm.nih.gov. The safety and efficacy of four different fixed combination regimens of adapalene 0.1%/benzoyl peroxide 2.5% gel for the treatment of acne vulgaris: results from a randomised controlled study [Internet]. Accessed 3 November 2026. View source ↗
8. American Academy of Dermatology. Acne: Diagnosis and treatment [Internet]. Accessed 3 November 2026. View source ↗
9. American Academy of Dermatology. Moisturizer: Why you may need it if you have acne [Internet]. Accessed 3 November 2026. View source ↗
10. NHS. Benzoyl peroxide: a medicine to treat acne - NHS [Internet]. Accessed 3 November 2026. View source ↗
11. pmc.ncbi.nlm.nih.gov. Interventions to increase adherence to acne treatment [Internet]. Accessed 3 November 2026. View source ↗
12. Baldwin H, Frey C, Hebert A, Lain ET, Schlesinger T. An Algorithm Integrating Acneceuticals into the Management of Acne Vulgaris. J Drugs Dermatol. 2025;24(4):376–380. doi:10.36849/JDD.8887. View source ↗
13. Tempark T, Shem A, Lueangarun S. Efficacy of ceramides and niacinamide-containing moisturizer versus hydrophilic cream in combination with topical anti-acne treatment in mild to moderate acne vulgaris: A split face, double-blinded, randomized controlled trial. J Cosmet Dermatol. 2024;23(5):1758–1765. doi:10.1111/jocd.16212. View source ↗
14. American Academy of Dermatology. Acne clinical guideline [Internet]. Accessed 3 November 2026. View source ↗
15. National Institute for Health and Care Excellence. Overview [Internet]. Accessed 3 November 2026. View source ↗
16. National Institute for Health and Care Excellence. Acne vulgaris: management (NG198). Recommendations, section 1.2: skin care advice. Updated 30 April 2026. View recommendations ↗
17. Nast A et al. EuroGuiDerm Guideline for the Treatment of Acne: Update 2025. European Dermatology Forum. Section 2.4, vehicle considerations. View guideline ↗

Evidence note. The 2014 moisturiser recommendations are expert consensus rather than a patient-level adherence measurement. The 2026 adherence review synthesised heterogeneous observational studies; reported estimates ranged from 6% to 84%, with larger studies estimating 50–65%. The 2024 adult-acne consensus received an educational grant and disclosed author meeting fees. Its descriptions of supporting trials should be read alongside the primary study when available. These evidence types are kept separate in the discussion and comparison above.^{1, 2, 6}